The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic fibrosis (CF) as young as 6 who have the most common type of CF-causing mutation. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. approved a similar expansion. “Today both the European Commission and MHRA have agreed to license Kaftrio for use in children aged 6–11 years old. More than 1,500 children across the UK and…

You must be logged in to read/download the full post.